Related Experiment Videos

Crystal structure of aurora-2, an oncogenic serine/threonine kinase

Graham M T Cheetham1, Ronald M A Knegtel, Joyce T Coll

  • 1Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom. cheetham@vpharm.com

Insights

Aurora-2 kinase, a target for cancer therapy, has its crystal structure revealed. This finding aids in designing potent inhibitors to block cancer cell proliferation.

Area of Science:

  • Molecular Biology
  • Structural Biology
  • Oncology

Background:

  • Aurora-2 is a serine/threonine kinase crucial for mitosis.
  • It is oncogenic and amplified in human cancers, making it a therapeutic target.
  • Inhibiting Aurora-2 can disrupt the cell cycle and block cancer proliferation.

Purpose of the Study:

  • To determine the first crystal structure of Aurora-2 kinase.
  • To analyze the active site and activation loop for drug design insights.
  • To provide a basis for developing selective ATP-competitive inhibitors.

Main Methods:

  • X-ray crystallography was used to obtain the Aurora-2 kinase structure.
  • The structure was determined in complex with adenosine.
  • Analysis focused on active site residues and the activation loop conformation.

Main Results:

  • The first crystal structure of Aurora-2 kinase bound to adenosine is reported.
  • Active site analysis revealed differences compared to related kinases.
  • A unique conformation of the Aurora kinase-specific activation loop was observed.

Conclusions:

  • The determined structure provides valuable insights into Aurora-2 kinase.
  • Understanding the active site and activation loop is key for inhibitor design.
  • These findings facilitate the development of selective and potent ATP-competitive inhibitors for Aurora kinases.

Related Concept Videos